Industry Wire 206

September 3, 2024 Jake Fishman 0 min read
  1. Oregon’s hospital price cap cut patient costs, increased utilization.
  2. U.S. govt warns hospitals of Iran-based ransomware attacks.
  3. Minnesota’s CentraCare launches $230M outpatient expansions.
  4. AI remains the most exciting emerging healthcare tech.
  5. San Diego’s Sharp HealthCare and Palomar Health launch partnership.
  6. Cedars-Sinai raises $1B for research, clinical care, and academic leadership.
  7. HCA completes acquisition of Valesco physician practice management firm.
  8. TennCare intentionally kept patients from care.
  9. HHS cancels appeal on hospital web tracker decision.
  10. How McLaren Port Huron Hospital used paper records after cyberattack.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]